Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
Second PhIII study for Idorsia's sleep drug returns positive results, but also raises new questions
Following a successful Phase III study in April showcasing the safety and potential of its new sleep drug, Idorsia posted some mixed news in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
